Skip to main content

Table 1 Baseline characteristics of enrolled HCC patients

From: Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

Variable

All patients

Tumor occupation ≥50%

Invasion with Vp4

Yes

No

Yes

No

Sample size

n = 84

n = 31

n = 53

n = 30

n = 54

Median age (range)

53 (25–78)

51 (29–78)

53 (25–72)

51 (29–78)

53 (25–78)

Sex

 Male

69 (82.1)

25 (80.6)

44 (83.0)

25 (83.3)

44 (81.5)

 Female

15 (17.9)

6 (19.4)

9 (17.0)

5 (16.7)

10 (18.5)

HBsAg

 Positive

71 (84.5)

26 (83.9)

45 (84.9)

28 (93.3)

43 (79.6)

 Negative

13 (15.5)

5 (16.1)

8 (15.1)

2 (6.7)

11 (20.4)

Child-Pugh class

 A

72 (85.7)

23 (74.2)

49 (92.5)

25 (83.3)

47 (87.0)

 B

12 (14.3)

8 (25.8)

4 (7.5)

5 (16.7)

7 (13.0)

BCLC stage

 B

15 (17.9)

4 (12.9)

11 (20.8)

0 (0.0)

15 (27.8)

 C

69 (82.1)

27 (87.1)

42 (79.2)

30 (100.0)

39 (72.2)

Extrahepatic metastasis

 Yes

42 (50.0)

13 (41.9)

29 (54.7)

12 (40.0)

30 (55.6)

 No

42 (50.0)

18 (58.1)

24 (45.3)

18 (60.0)

24 (44.4)

AFP level ≥ 400 μg/ml

 Yes

45 (53.6)

20 (64.5)

25 (47.2)

19 (63.3)

26 (48.1)

 No

39 (46.4)

11 (35.5)

28 (52.8)

11 (36.7)

28 (51.9)

Prior systemic treatment

 Yes

10 (11.9)

5 (16.1)

5 (9.4)

0 (0.0)

10 (18.5)

 No

74 (88.1)

26 (83.9)

48 (90.6)

30 (100.0)

44 (81.5)

Prior TACE

 Yes

33 (39.3)

9 (29.0)

24 (45.3)

8 (26.7)

25 (46.3)

 No

51 (60.7)

22 (71.0)

29 (54.7)

22 (73.3)

29 (53.7)

Maximum diameter of HCC ≥ 5 cm

 Yes

64 (76.2)

30 (96.8)

34 (64.2)

27 (90.0)

37 (68.5)

 No

20 (23.8)

1 (3.2)

19 (35.8)

3 (10.0)

17 (31.5)